金融界消息 截至2025年8月5日收盘，甘李药业（603087）报收于63.69元，上涨0.65%，换手率3.47%， 成交量19.48万手，成交金额12.43亿元。 资金流向方面，今日主力资金净流入4266.56万元，占比成交额3.43%。其中，超大单净流入3873.58万 元、占成交额3.12%，大单净流入392.98万元、占成交额0.32%，中单净流出流出1940.72万元、占成交 额1.56%，小单净流出2325.84万元、占成交额1.87%。 甘李药业最新一期业绩显示，截至2025一季报，公司营业总收入9.85亿元、同比增长75.76%，归属净利 润3.12亿元，同比增长224.90%，扣非净利润2.15亿元，同比增长1150.17%，流动比率4.917、速动比率 3.514、资产负债率7.91%。 天眼查商业履历信息显示，甘李药业股份有限公司，成立于1998年，位于北京市，是一家以从事医药制 造业为主的企业。企业注册资本60106.529万人民币，实缴资本60106.529万人民币。公司法定代表人为 陈伟。 通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2427次， ...

Core Viewpoint - Gann Li Pharmaceutical Co., Ltd. has shown significant financial growth in the first quarter of 2025, with a notable increase in revenue and net profit, indicating strong operational performance and potential investment opportunities [1][2]. Financial Performance - As of the first quarter of 2025, Gann Li reported total revenue of 985 million yuan, representing a year-on-year growth of 75.76% [1]. - The company's net profit attributable to shareholders reached 312 million yuan, a year-on-year increase of 224.90% [1]. - The non-recurring net profit was 215 million yuan, showing a remarkable year-on-year growth of 1150.17% [1]. - The liquidity ratios are strong, with a current ratio of 4.917 and a quick ratio of 3.514, while the debt-to-asset ratio stands at 7.91% [1]. Market Activity - On August 4, 2025, Gann Li's stock closed at 63.26 yuan, up 3.72%, with a turnover rate of 4.55% and a trading volume of 255,400 hands, amounting to a transaction value of 1.579 billion yuan [1]. - The net inflow of main funds was 186 million yuan, accounting for 11.89% of the transaction value, with large orders contributing a net inflow of 112 million yuan [1]. Company Background - Gann Li Pharmaceutical Co., Ltd. was established in 1998 and is based in Beijing, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 6.0106529 billion yuan and has made investments in six enterprises, participated in 2,427 bidding projects, and holds 190 trademark registrations and 103 patents [2].

Core Insights - The event held on August 2 in Beijing aimed to connect high-level talents with quality enterprises, significantly enhancing the recruitment efforts for the city's sub-center development [1][16] - Nearly 50 key enterprises participated, offering over 600 quality job positions, showcasing the sub-center's strong appeal to high-end talent [1][3] Talent Attraction - The recruitment event attracted over 1,400 candidates, with nearly 1,000 attending in person, resulting in 500 preliminary employment intentions [3] - The talent pool was diverse, including 251 overseas returnees and 310 individuals with master's degrees or higher, indicating a high level of educational attainment [5] Industry Alignment - Popular sectors among candidates included finance, internet, AI, advertising, media, culture, and sports, aligning well with the sub-center's key industries [7] - Participating companies included major players such as Industrial and Commercial Bank of China, Mengniu Dairy, and China Three Gorges Corporation, reflecting a rich variety of industry representation [8] Event Experience - The event featured a high level of engagement, with candidates actively interacting with HR representatives, leading to a positive experience for job seekers [12][14] - Specialized service areas, such as career planning and policy consultation, attracted significant attention, with over 500 and 1,500 visits respectively [14] Future Initiatives - The event organizer plans to follow up on the employment status of interested candidates and introduce more workplace experiences and internship opportunities [16] - The local talent bureau aims to optimize employment services and maintain a consistent recruitment effort to support the sub-center's high-quality development [20]

Group 1: Investor Meeting Announcement - The company will hold a half-year performance briefing on August 13, 2025, from 10:00 to 11:00 AM [2][8] - Investors can submit questions from August 6 to August 12, 2025, via the Shanghai Stock Exchange Roadshow Center or the company's email [2][9] - The meeting will be conducted in an interactive online format, allowing for real-time communication with investors [3] Group 2: Attendance and Participation - Key personnel attending the meeting include the Chairman, General Manager, Independent Director, and other senior management [4] - Investors can participate in the meeting by logging into the Shanghai Stock Exchange Roadshow Center [6][7] - The meeting will be accessible online, and investors can view the main content afterward [10] Group 3: Share Buyback Progress - The company approved a share buyback plan on September 5, 2024, with a maximum price of RMB 62.76 per share and a total buyback fund between RMB 150 million and RMB 300 million [12] - As of July 31, 2025, the company has repurchased 3.540021 million shares, accounting for 0.5890% of the total share capital, with a total expenditure of approximately RMB 150.07 million [15] - The purpose of the buyback has been adjusted from employee stock ownership plans to reducing the company's registered capital [13]

Core Viewpoint - Ganli Pharmaceutical announced that it will not repurchase shares by July 2025 [2] Summary by Relevant Sections - Company Announcement - Ganli Pharmaceutical released a statement on August 1, indicating that it will not engage in share repurchases until July 2025 [2]

Core Viewpoint - Ganne Li Pharmaceutical announced that it will hold a semi-annual performance briefing on August 13, 2025, from 10:00 to 11:00 AM [2] Company Summary - The company is scheduled to present its half-year performance results for 2025 [2]

金融界消息 截至2025年8月1日收盘，甘李药业（603087）报收于60.99元，上涨5.34%，换手率5.14%， 成交量28.84万手，成交金额17.55亿元。 资金流向方面，今日主力资金净流入3409.28万元，占比成交额1.94%。其中，超大单净流入6145.27万 元、占成交额3.5%，大单净流出2736.00万元、占成交额1.56%，中单净流出流出3790.35万元、占成交 额2.16%，小单净流入381.07万元、占成交额0.22%。 天眼查商业履历信息显示，甘李药业股份有限公司，成立于1998年，位于北京市，是一家以从事医药制 造业为主的企业。企业注册资本60106.529万人民币，实缴资本60106.529万人民币。公司法定代表人为 陈伟。 通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2427次，知识 产权方面有商标信息190条，专利信息103条，此外企业还拥有行政许可449个。 来源：金融界 甘李药业最新一期业绩显示，截至2025一季报，公司营业总收入9.85亿元、同比增长75.76%，归属净利 润3.12亿元，同比增长224.90%，扣非净利润2.15 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-056 甘李药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 重要内容提示： 公司将于 2025 年 8 月 8 日在上海证券交易所网站（www.sse.com.cn）披露 《2025 年半年度报告》。为便于广大投资者更全面深入地了解公司状况，公司决 定于 2025 年 8 月 13 日上午 10:00-11:00 举行 2025 年半年度业绩说明会，对公司 的经营业绩、公司战略等具体情况进行充分交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度公司的 经营业绩、公司战略等具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2025 年 8 月 13 日（星期三）上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinf o.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 6 日（星期三）至 8 月 12 日 ...

格隆汇8月1日丨甘李药业(603087.SH)公布，截至2025年7月31日，公司已累计回购股份354.0021万股， 占公司总股本的比例为0.5890%，成交最高价为45.14元/股，成交最低价为37.65元/股，已支付的资金总 额约为人民币15,006.9654万元（不含交易费用）。 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-057 甘李药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/9/6 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2024 9 9 4 | 5 日~2025 | 年 | 日 | | 预计回购金额 | 15,000万元~30,000万元 | | | | | 回购用途 | √减少注册资本 | | | | | | □用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 354.0021万股 | | | | | 累计已回购股数占总股本比例 | 0.5890% | | | | | 累计已回购金额 | 15,006.9654万元 | | | | | 实际回购价格区间 | 37.65元/股~45. ...